stockportfolio.pro
NTRA vs ONC: Which Stock Is the Better Buy?
Natera, Inc. and BeOne Medicines AG side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — NTRA vs ONC, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Natera, Inc. (NTRA) | BeOne Medicines AG (ONC) | |
|---|---|---|
| Market cap | $31.0B | $27.0B |
| Revenue (latest FY) | $2.31B | $5.34B |
| Net income (latest FY) | $-208.16M | $286.93M |
| Revenue growth (5y CAGR) | 42.6% | 76.8% |
| Net margin | -9.0% | 5.4% |
| Return on equity | -12.2% | 6.6% |
| P/E ratio | — | 58.8 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | Yes | Yes |
See the full NTRA vs ONC breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open NTRA's full financials → Open ONC's full financials →More comparisons
Frequently asked questions
Which is bigger, NTRA or ONC?
Natera, Inc. is larger by market capitalization — $31.0B versus $27.0B.
Which grows faster, NTRA or ONC?
Over the last five fiscal years, BeOne Medicines AG grew revenue faster — 76.8%/yr versus 42.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
NTRA fundamentals → · ONC fundamentals → · All 1,500+ companies → · Free screener →